2. Fattovich G., Bertoletti F., Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J. Hepatol. 2008; 48, 335–52. doi: 10.1016/j.jhep.2007.11.011

3. MacLachlan J.H.,Cowie B.C. Hepatitis B virus epidemiology. Cold Spring Harb. Perspect. Med. 2015; 5(5): a021410. doi: 10.1101/cshperspect. a021410

4. Ющук Н.Д., Климова Е.А., Знойко О.О., Кареткина Г.Н., Максимов С.Л., Маев И.В. Вирусные гепатиты. Клиника, диагностика, лечение. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015. 302 с.

Yushchuk N.D., Klimova E.A., Znoуko O.O., Karetkina G.N.. Maksimov S.L., Mayev I.V.

5. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 286 с.

Abdurakhmanov D.T.

6. Weinbaum C., Williams I., Mast E., Wang S.A., Finelli L., Wasley A. et al. Recommendations for identication and public health manage-ment of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 2008; 57: 1–20.

7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of chronic hepatitis В virus infection. J. Hepatol. 2017; 67(2): 370–98. doi: 10.1016/j.jhep.2017.03.021

8. Chou R., Dana T., Bougatsos S., Blazina I., Khangura J., Zakher B. Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann. Intern. Med. 2014; 161: 31–45. doi: 10.7326/M13-2837

9. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S.F. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 2007; 45(4): 1056–75. DOI: 10.1002/hep.21627

10. Sweetman S., ed. Martindale: the complete drug reference (online version), 37th edition, 2011. http://www.pharmpress.com/product/MC_MART/ martindale-the-complete-drug-reference

11. Terrault N.A., Lok A.S., McMahon B.J., Chang K.-M., Hwang J/P., Jonas M.M. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67(4): 1560–99. doi: 10.1002/hep.29800

12. Schiff E.R., Lee S.S., Chao Y.C., You-Chen Chao, Seung Kew Yoon et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2011; 9(3): 274–6. DOI: 10.1016/j.cgh.2010.11.040

13. Yeo Y.H., Ho H.J., Yang H.I., Tseng T.C., Hosaka T., Trinh H.N. et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology 2019; 156(3): 635–646.e9. doi: 10.1053/j.gastro.2018. 10.027

14. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45(5): 1187–92. doi: 10.1002/hep.21612

15. Okada M., Enomoto M., Kawada N.,Nguyen M.N. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis . Expert Rev. Gastroenterol. Hepatol. 2017; 11: 1095–104. DOI: 10.1080/17474124. 2017. 1361822

16. Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381(9865): 468–75. DOI: 10.1016/S0140-6736(12)61425-1

17. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. J Hepatol 2017; 67 (2): 370–398. DOI: 10.1016/j.jhep.2017.03.021